...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith AGM Corporation Update Slides and Webcast

Bear,   Hopefully the Phase 2a mCRPC trial  results are good, but Zenith has yet been able to garnish a large BP partner.  I think Zenith needs a large BP partner  to help legitimize the epigenetics science to the next level .   A BP deal might even help RVX SP for a pending deal on all data related to the BOM trial.

 

Science side is great for both companies  , business side not so good yet.....

Share
New Message
Please login to post a reply